Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SaveMinD: SGLT2 Inhibitors for Cognitive Decline in Type 2 Diabetes
NCT07694596Active, not recruiting
- Sponsor
- University of Primorska
- Start
- Jun 2026
- Primary completion
- Apr 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in cognitive dysfunction and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University of Primorska. Primary endpoint: Change in Executive Cognitive Composite Score at 12 months. Started Jun 2026; status: active, not recruiting.
02
Conditions
cognitive dysfunctiontype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07694596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694596.